Which of the following is true concerning the use of cannabinoids for multiple sclerosis?
A. patients struggle with the side effects making this product unuseful
B. patients report improved spasticity
C. patients don't notice a difference, but lab results show an improvement
D. clinicians report an improvement in spasticity